The Upstart Heart Drug That's Beating the Billion-Dollar Incumbent
BridgeBio's acoramidis just posted real-world data showing it outperformed Pfizer's entrenched tafamidis in nearly 2,700 heart patients. In a market worth billions, the new kid on the block is making a very compelling case.
Imagine you've been the only restaurant on the block for years. Great reviews, loyal customers, no real competition. Then a new place opens next door, and the Yelp reviews start rolling in: better food, better service, better everything. That's roughly what just happened to Pfizer's tafamidis.
BridgeBio dropped a real-world evidence bomb at the HFSA Annual Scientific Meeting, and the results are raising eyebrows across cardiology. Their drug acoramidis (brand name Attruby) didn't just match the longtime standard of care in ATTR cardiomyopathy; it beat it by a meaningful margin across multiple measures.
What Actually Happened
Researchers used the Epic COSMOS platform, one of the largest electronic health record databases in the U.S., to compare patients taking acoramidis against those on tafamidis. This wasn't a company-run clinical trial. It was an independent, observational look at what's happening in real hospitals with real patients.
The study tracked 2,684 patients using a propensity score-matched analysis (a statistical technique that tries to make apples-to-apples comparisons when you can't randomize). The headline number: acoramidis was associated with an 18% lower risk of a composite that included death, hospitalization, new-onset atrial fibrillation, and escalation of diuretics.
That's a statistically significant hazard ratio of 0.82, with a p-value below 0.01. In human terms: patients on the newer drug were less likely to end up back in the hospital or get sicker.
The Numbers Get Even More Interesting
The composite result is impressive, but the individual components tell a sharper story. Acoramidis was tied to a 27% lower risk of cardiovascular hospitalization and a 27% lower risk of heart failure hospitalization specifically. All-cause hospitalization dropped by 25%.
The reductions in death and new-onset atrial fibrillation numerically favored acoramidis too, though those didn't appear to be the strongest statistical drivers. Fewer events and limited follow-up likely explain that; it takes more time (and more patients) to see mortality differences emerge clearly.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Still, the hospitalization story alone is significant. Heart failure hospitalizations are expensive, miserable, and often the beginning of a downward spiral. If you can keep patients out of the hospital more often, you're doing something that matters to patients, families, and the healthcare system.
Same Mechanism, Different Results?
This is where things get a little puzzling. Acoramidis and tafamidis work the same way. Both are TTR stabilizers, meaning they grab onto a protein called transthyretin and prevent it from falling apart into toxic fragments that damage the heart. Think of transthyretin like a Jenga tower: in ATTR cardiomyopathy, the blocks start slipping, and the debris builds up in heart tissue. Both drugs essentially glue the tower together.
The difference is in the engineering. Acoramidis was designed to bind more tightly, forming two hydrogen bonds in the binding pocket and mimicking a naturally protective genetic variant. BridgeBio has called it a "near-complete" stabilizer, aiming for over 90% stabilization. Tafamidis is the original, the proven standard, but the newer drug was built specifically to outperform it.
Here's the twist, though: in laboratory head-to-head comparisons at clinically relevant drug levels, some researchers have found no significant difference in biochemical potency between the two. So how do you explain better real-world outcomes if the test-tube performance looks similar? That's a question that will keep pharmacologists busy for a while.
The Fine Print Matters
Before anyone declares a new king, a few caveats. This is observational data, not a randomized controlled trial. That distinction is enormous in medicine.
Observational studies can show associations, but they can't prove that Drug A caused better outcomes than Drug B. There's always the lurking possibility of confounding by indication: maybe the patients who got acoramidis were systematically different from those who got tafamidis in ways the statistical matching couldn't fully capture. Perhaps they were younger, diagnosed earlier, or seen at academic medical centers with better overall care.
EHR data also has well-known blind spots. Key variables like frailty, functional status, and genotype details might be missing or inconsistently recorded. Diagnostic codes don't always reflect the full clinical picture, and treatment adherence is notoriously hard to track through medical records alone.
None of this makes the study worthless. It makes it what all real-world evidence is: a strong signal that needs further confirmation, not a verdict.
A Multi-Billion-Dollar Tug of War
The financial stakes here are massive. Estimates for the ATTR cardiomyopathy treatment market in 2026 range from roughly $4 billion to $17 billion, depending on how broadly you define the space. That's a wide spread, but even the low end represents a huge prize. Tafamidis (sold by Pfizer as Vyndaqel and Vyndamax) has been the dominant player for years, building an enormous revenue base with limited competition.
Acoramidis is the challenger, still building prescription volume and payer relationships. Data like this real-world study could accelerate that process by giving doctors and insurers a concrete reason to consider switching. It also builds on acoramidis's already strong clinical foundation: the ATTRibute-CM pivotal trial enrolled 632 patients and hit its primary endpoint with a p-value below 0.0001, showing a win ratio of 1.8 for a four-component hierarchical composite endpoint including all-cause mortality, cardiovascular hospitalization, NT-proBNP change, and 6-minute walk distance versus placebo.
Wall Street's Verdict: Cautiously Optimistic
Analysts didn't exactly throw a parade, but they didn't ignore the data either. The consensus on BridgeBio remained a Strong Buy. Barclays kept its Overweight rating, and H.C. Wainwright reiterated a Buy.
The muted reaction makes sense. Real-world evidence is supportive, not transformative, in the eyes of most institutional investors. It strengthens the case for gradual market share gains, but it doesn't replace the need for ongoing prescription momentum and payer coverage wins. The Street sees upside but wants to see the commercial ramp continue before getting truly excited.
The Bottom Line
BridgeBio now has two layers of evidence working in its favor: a strong randomized trial and a large, independent real-world study both pointing in the same direction. That's a compelling combination, even if the observational data comes with caveats.
For Pfizer, this isn't a crisis, but it's a warning sign. When an upstart starts posting better real-world numbers in a market worth billions, the prescribing conversation changes. Doctors talk to each other. Formulary committees take notice. And gradually, the default choice can shift.
The next chapter will depend on whether these real-world trends hold up with longer follow-up and whether a head-to-head randomized trial ever materializes. Until then, acoramidis just gave itself the strongest argument yet that being second to market doesn't mean being second best.
4 min read
GSK Thinks It Can Build a Better Flu Shot With mRNA
GSK's mRNA flu vaccine just beat both standard and high-dose flu shots in a mid-stage trial of 971 adults. Now it's heading to Phase 3, putting GSK squarely in Moderna's rearview mirror in the race to reinvent the annual flu shot.
